中牧股份(600195.SH)控股子公司通過獸藥GMP驗收並取得證書
格隆匯11月11日丨中牧股份(600195.SH)公佈,經過檢查和驗收審核,中牧實業股份有限公司控股子公司湖北中牧安達藥業有限公司申請驗收的生產線符合《獸藥生產質量管理規範》的要求,通過了獸藥GMP驗收,湖北省農業農村廳近日核發了《獸藥生產許可證》和《獸藥GMP證書》。
驗收範圍:非無菌原料藥(氟苯尼考、替米考星、地美硝唑、阿苯達唑、氟尼辛葡甲胺、硫酸頭孢喹肟、乙酰甲喹、尼卡巴嗪)
獸藥生產許可證證號:(2020)獸藥生產證字17006號
獸藥生產許可證有效期:2020年11月4日至2025年11月3日
獸藥GMP證書證號:(2020)獸藥GMP證字17007號
獸藥GMP證書有效期:2020年11月4日至2025年11月3日
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.